Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

45.30 +0.60 (+1.34%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca... 
Via MarketMinute
FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
89bio Stock Skyrockets After Roche’s $3.5B Buyout Offer: Retail Bullish, But A Wall Street Analyst Is Cautious
Via Stocktwits
Why Did 89bio Stock Nearly Double In Value Today?
Via Stocktwits
Big Pharma Eyes China: J&J And Roche Reportedly In Talks For Henlius’ Experimental Cancer Drug
Via Stocktwits
Novartis Rides Bullish Retail Mood, Roche Faces Gloom Amid Swiss-US Trade Concerns
Via Stocktwits
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
From Genentech
Via Business Wire
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
Roche Targets Top Spot In Weight Loss Drug Market
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
From Genentech
Via Business Wire
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
The Healthcare Horizon: Navigating Innovation, Policy Shifts, and Evolving Patient Care
The global healthcare industry is currently in the midst of a profound metamorphosis, characterized by a rapid influx of technological innovation, significant shifts in policy, and evolving patient... 
Via MarketMinute
Topics Artificial Intelligence
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It
The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desperate for deal approval. 
Via Benzinga
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug pegozafermin. 
Via Benzinga
Roche Digs Into Obesity-Tied Diseases With $3.5 Billion 89bio Buyout
The company is now focusing on MASH, a form of fatty liver disease common in people with obesity and type 2 diabetes. 
Via Investor's Business Daily
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
The positives for this big drugmaker appear to outweigh the negatives. 
Via The Motley Fool
Topics Earnings Government World Trade
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study. 
Via Investor's Business Daily
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China. 
Via Benzinga
2 High-Yield Dividend ETFs You Can Buy With $200 in September and Hold Forever
You don't need to be rich to begin building a passive income stream that could fuel your retirement dreams. 
Via The Motley Fool
Topics ETFs Retirement Stocks
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Genentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled Hypertension
From Genentech
Via Business Wire
Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
From Genentech
Via Business Wire
2 Brilliant Vanguard Index Funds to Buy With $1,000 in August and Hold Forever
These Vanguard index funds offer diversified exposure to many of the most influential stocks in the world. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.